UNITED THERAPEUTICS Corp
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 1000 SPRING ST, SILVER SPRING, MD, 20910
Mailing Address 1000 SPRING ST, SILVER SPRING, MD, 20910
Phone 3016089292
Fiscal Year End 1231
EIN 521984749
Financial Overview
FY2025
$783.80M
Total Liabilities
$4.80B
Stockholders' Equity
$30.13
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 24, 2026 | View on SEC |
| 4 Insider stock transaction report | March 24, 2026 | View on SEC |
| 4 Insider stock transaction report | March 24, 2026 | View on SEC |
Annual Reports
10-K February 25, 2026
- Achieved robust financial growth in 2024, with total net product sales reaching $3.029 billion, a 20.6% increase.
- Tyvaso products drove significant growth, with sales surging 31.4% to $1.559 billion and accounting for over half of total revenue.
Insider Trading
STRONG SELL 12 insiders
100 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.